Cargando…

The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients

BACKGROUND: Growth hormone deficiency (GHD) has been implicated in increased cardiovascular and cerebrovascular disease risk seen in hypopituitarism, however the mechanism remains speculative. We hypothesise that platelet abnormalities may play a contributory role. Herein we examined platelet behavi...

Descripción completa

Detalles Bibliográficos
Autores principales: Oglesby, Irene K, Slattery, David, Glynn, Nigel, Gupta, Saket, Duggan, Karen, Cuesta, Martin, Dunne, Eimear, Garrahy, Aoife, Toner, Siobhan, Kenny, Dermot, Agha, Amar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500895/
https://www.ncbi.nlm.nih.gov/pubmed/37705005
http://dx.doi.org/10.1186/s12902-023-01448-6
_version_ 1785106012656631808
author Oglesby, Irene K
Slattery, David
Glynn, Nigel
Gupta, Saket
Duggan, Karen
Cuesta, Martin
Dunne, Eimear
Garrahy, Aoife
Toner, Siobhan
Kenny, Dermot
Agha, Amar
author_facet Oglesby, Irene K
Slattery, David
Glynn, Nigel
Gupta, Saket
Duggan, Karen
Cuesta, Martin
Dunne, Eimear
Garrahy, Aoife
Toner, Siobhan
Kenny, Dermot
Agha, Amar
author_sort Oglesby, Irene K
collection PubMed
description BACKGROUND: Growth hormone deficiency (GHD) has been implicated in increased cardiovascular and cerebrovascular disease risk seen in hypopituitarism, however the mechanism remains speculative. We hypothesise that platelet abnormalities may play a contributory role. Herein we examined platelet behaviour in GHD hypopituitary patients, pre- and post-growth hormone (GH) replacement. METHODS: This study utilizes a physiological flow-based assay to quantify platelet function in whole blood from patient cohorts under arterial shear. Thirteen GH Naïve hypopituitary adults with GHD and thirteen healthy matched controls were studied. Patients were assessed before and after GH treatment. All other pituitary replacements were optimised before the study. In addition to a full endocrine profile, whole blood was labelled and perfused over immobilised von Willibrand factor (vWF). Seven parameters of dynamic platelet-vWF interactions were recorded using digital image microscopy and analysed by customised platelet tracking software. RESULTS: We found a significantly altered profile of platelet-vWF interactions in GHD individuals compared to healthy controls. Specifically, we observed a marked increase in platelets shown to form associations such as tethering, rolling and adherence to immobilized vWF, which were reduced post GH treatment. Speed and distance platelets travelled across vWF was similar between controls and pre-therapy GHD patients, however, this was considerably increased post treatment. This may indicate reduced platelet signaling resulting in less stable adhesion of platelets post GH treatment. CONCLUSIONS: Taken together observed differences in platelet behaviour may contribute to an increased risk of thrombosis in GHD which can in part be reversed by GH therapy.
format Online
Article
Text
id pubmed-10500895
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105008952023-09-15 The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients Oglesby, Irene K Slattery, David Glynn, Nigel Gupta, Saket Duggan, Karen Cuesta, Martin Dunne, Eimear Garrahy, Aoife Toner, Siobhan Kenny, Dermot Agha, Amar BMC Endocr Disord Research BACKGROUND: Growth hormone deficiency (GHD) has been implicated in increased cardiovascular and cerebrovascular disease risk seen in hypopituitarism, however the mechanism remains speculative. We hypothesise that platelet abnormalities may play a contributory role. Herein we examined platelet behaviour in GHD hypopituitary patients, pre- and post-growth hormone (GH) replacement. METHODS: This study utilizes a physiological flow-based assay to quantify platelet function in whole blood from patient cohorts under arterial shear. Thirteen GH Naïve hypopituitary adults with GHD and thirteen healthy matched controls were studied. Patients were assessed before and after GH treatment. All other pituitary replacements were optimised before the study. In addition to a full endocrine profile, whole blood was labelled and perfused over immobilised von Willibrand factor (vWF). Seven parameters of dynamic platelet-vWF interactions were recorded using digital image microscopy and analysed by customised platelet tracking software. RESULTS: We found a significantly altered profile of platelet-vWF interactions in GHD individuals compared to healthy controls. Specifically, we observed a marked increase in platelets shown to form associations such as tethering, rolling and adherence to immobilized vWF, which were reduced post GH treatment. Speed and distance platelets travelled across vWF was similar between controls and pre-therapy GHD patients, however, this was considerably increased post treatment. This may indicate reduced platelet signaling resulting in less stable adhesion of platelets post GH treatment. CONCLUSIONS: Taken together observed differences in platelet behaviour may contribute to an increased risk of thrombosis in GHD which can in part be reversed by GH therapy. BioMed Central 2023-09-14 /pmc/articles/PMC10500895/ /pubmed/37705005 http://dx.doi.org/10.1186/s12902-023-01448-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Oglesby, Irene K
Slattery, David
Glynn, Nigel
Gupta, Saket
Duggan, Karen
Cuesta, Martin
Dunne, Eimear
Garrahy, Aoife
Toner, Siobhan
Kenny, Dermot
Agha, Amar
The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
title The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
title_full The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
title_fullStr The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
title_full_unstemmed The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
title_short The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
title_sort modulation of platelet function by growth hormone in growth hormone deficient hypopituitary patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500895/
https://www.ncbi.nlm.nih.gov/pubmed/37705005
http://dx.doi.org/10.1186/s12902-023-01448-6
work_keys_str_mv AT oglesbyirenek themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT slatterydavid themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT glynnnigel themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT guptasaket themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT duggankaren themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT cuestamartin themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT dunneeimear themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT garrahyaoife themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT tonersiobhan themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT kennydermot themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT aghaamar themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT oglesbyirenek modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT slatterydavid modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT glynnnigel modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT guptasaket modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT duggankaren modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT cuestamartin modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT dunneeimear modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT garrahyaoife modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT tonersiobhan modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT kennydermot modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients
AT aghaamar modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients